Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

• Published in: BMC cancer Vol. 23; no. 1; pp. 1 - 1006
• Main Authors: Xu, Huilin, Cao, Dedong, Zhou, Dingjie, Zhao, Nan, Tang, Xixian, Shelat, Vishalkumar G, Samant, Hrishikesh, Satapathy, Sanjaya K, Tustumi, Francisco, Aprile, Giuseppe, He, Anbing, Xu, Ximing, Ge, Wei
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 19.10.2023; BioMed Central; BMC
• Subjects: Albumin; Albumin-bilirubin (ALBI); Analysis; Ascites; Bilirubin; Biomarker; Cancer therapies; Care and treatment; Chemotherapy; Diagnosis; Disease control; Estimates; Health aspects; Hepatitis; Hepatocellular carcinoma; Hepatocellular carcinoma (HCC); Hepatoma; Liver cancer; Liver function tests; Measurement; Medical prognosis; Medical research; Medicine, Experimental; Meta-analysis; Operating systems; Patient outcomes; Prognosis; Regorafenib; Statistical analysis; Survival; Systematic review; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11488-9

Background The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker for regorafenib treatment, but its prognostic value remains controversial. Therefore, we conducted a meta-analysis to investigate the value of the baseline ALBI grade in predicting the efficacy and survival outcomes of HCC patients after regorafenib treatment. Methods PubMed, Embase, Cochrane library, Web of Science, CNKI, Wan Fang Data, and Vip Database were searched from January 2010 to October 2022. Studies treating HCC patients with regorafenib and with ALBI as a categorical variable, overall survival (OS) and progression-free survival (PFS) as outcome indicators were included. After applying Newcastle-Ottawa Scale (NOS) to evaluate the quality of the included studies, Review Manager 5.4 was used to statistically analyze. Chi-square Q test and I.sup.2 statistics were used to detect heterogeneity. Funnel plot asymmetry, Egger's and Begg's test were used to evaluate publication bias. Results A total of 12 studies, comprising 1,918 patients, were included in the meta-analysis. The included studies were all evaluated as high quality. Compared to the high-grade baseline ALBI group, patients in the low-grade group had a longer survival time after receiving regorafenib and also more suitable for regorafenib treatment [odds ratio (OR) = 6.50, 95% confidence interval (CI): 2.22-18.96, P < 0.01]. The low-grade baseline ALBI group before sorafenib treatment was significantly correlated with better OS [hazard ratio (HR) = 2.36, 95% CI: 1.68-3.31, P < 0.00001] and PFS (HR = 1.56, 95% CI: 1.16-2.08, P = 0.003). Likewise, the low-grade baseline ALBI group before regorafenib was also significantly correlated with better OS (HR = 1.56, 95% CI: 1.15-2.13, P = 0.005) and PFS (HR = 2.06, 95% CI: 1.37-3.11, P = 0.0005). In addition, the ALBI grade was significantly correlated with disease control rate (DCR) (OR = 2.90, 95% CI: 1.45-5.79, P = 0.003), but not the objective response rate (OR = 1.98, 95% CI: 0.71-5.46, P = 0.19). Conclusions The baseline ALBI grade could be a valuable prognostic indicator for predicting response and outcomes in HCC patients treated with regorafenib. Keywords: Hepatocellular carcinoma (HCC), Regorafenib, Biomarker, Albumin-bilirubin (ALBI), Survival